Physician profile
Eric Michael Yuneman
NPI 1598393936
$496.79
in general payments reported to CMS, 2019-2025
10 companies · $363 in 2025
The $363 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $76.38 · 2024: $57.74 · 2025: $363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $497.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $496.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $114.33 | 2025 | Korlym |
| Novo Nordisk INC | $89.32 | 2024-2025 | Ozempic, Rybelsus |
| Exact Sciences Corporation | $77.25 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Ferring Pharmaceuticals INC. | $73.11 | 2023-2025 | Euflexxa |
| Takeda Pharmaceuticals U.S.A., INC. | $54.81 | 2024-2025 | Entyvio |
| Hydrocision, INC. | $23.24 | 2024 | Tenjet |
| Gilead Sciences, INC. | $19.00 | 2025 | |
| Janssen Biotech, INC. | $18.42 | 2025 | Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.32 | 2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $9.99 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Yuneman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.